A "new frontier" for in-clinic veterinary cancer screeningJuly 7, 2025Cancer screening can be a stressful time for clients. However, deep learning artificial intelligence (AI) is changing the game for cytology. AI Masses – a new addition to Zoetis’s Vetscan Imagyst® platform – offers veterinarians analysis of potentially cancerous cells at the point of care, for more timely and individualized diagnosis and treatment.
SPONSORED CONTENTSee What the ACVIM Recommends for Certain Types of Canine CHFSafe, effective treatment that's approved by the FDA for management of certain types of canine CHF. + Learn More
A New Way Forward in Canine Osteoarthritis: Targeting Pain and Inflammation at Its SourceJuly 1, 2025The traditional approach to canine osteoarthritis (OA) has largely focused on treatments such as NSAIDs, joint supplements, stem cell, PRP, and anti-nerve growth factor (anti-NGF) injections. This raises a critical question: What if we could do more than manage symptoms? What if we could target the inflammation driving the disease?
Nu.Q® Vet Cancer Test on the Element i+™ – the cancer detective in your clinicDecember 5, 2024To help elucidate the benefits of this test, Dr. Graham Bilbrough has compiled some common questions from veterinarians about Nu.Q.
Longhorned ticks: What to know about their unique characteristics and potential risksDecember 5, 2024Q&A with Kathryn E. Reif, MSPH, PhD
